AIMS Pharma Announces Positive Topline Results from Phase 3 Trial of Novabrin for Alzheimer's Disease

HOUSTON, TX â€“ AIMS Pharma today announced that its pivotal Phase 3 clinical trial, 'HOPE-1', evaluating the efficacy and safety of its lead candidate, Novabrin, in patients with mild-to-moderate Alzheimer's disease, met its primary endpoint. The study, which enrolled 1,250 patients, demonstrated a statistically significant slowing of cognitive decline as measured by the ADAS-Cog scale. The outcome was successful, and the company plans to submit a New Drug Application (NDA) to the FDA in the second half of the year.
